

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number  
**WO 2004/032922 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/4045**,  
31/422, 31/404, 31/405, 31/445, 31/216, 31/48, 31/192,  
31/18, 31/635, 31/506, A61P 25/06

SK10 4TG (GB). **MORRIS, Clive, Dylan** [GB/GB];  
AstraZeneca R & D Alderley, Alderley Park, Macclesfield,  
Cheshire SK10 4TG (GB).

(21) International Application Number:  
PCT/GB2003/004338

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
P O Box 272, Mereside, Alderley Park, Macclesfield,  
Cheshire SK10 4GR (GB).

(22) International Filing Date: 6 October 2003 (06.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0223367.4 9 October 2002 (09.10.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except MG, US*): **AS-  
TRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIM-  
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-  
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CURWEN, Jon,  
Owen** [GB/GB]; AstraZeneca R & D Alderley, Alderley  
Park, Macclesfield, Cheshire SK10 4TG (GB). **HUGHES,  
Andrew, Mark** [GB/GB]; AstraZeneca R & D Alder-  
ley, Alderley Park, Macclesfield, Cheshire SK10 4TG  
(GB). **JOHNSTONE, Donna** [GB/GB]; AstraZeneca  
R & D Alderley, Alderley Park, Macclesfield, Cheshire

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: 5-HT<sub>1B/1D</sub> RECEPTOR AGONISTS FOR THE TREATMENT OF HEADACHE RESULTING FROM ADMINIS-  
TERING AN ENDOTHELIN RECEPTOR ANTAGONIST

(57) Abstract: The use of a 5-HT<sub>1B/1D</sub> receptor agonist in the treatment or prevention of headache that results from administering an  
endothelin receptor antagonist; and the combination, comprising an endothelin receptor antagonist and a 5-HT<sub>1B/1D</sub> receptor agonist  
is described.



WO 2004/032922 A1